Market Overview

Vetr Upgrade's REGN's On Price Growth Following Positive Guidance

Related REGN
Lightning Round: Jim Cramer Advises His Viewers On Chegg, Floor & Decor, Regeneron, And More
How To Trade The JPMorgan Healthcare Conference
Regeneron's Dupixent OK'd in Japan for atopic dermatitis (Seeking Alpha)

The Vetr crowd upgraded its rating for Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) from 1 star (Strong Sell), issued three days ago, to 3 stars (Hold). Crowd sentiment at the time of the downgrade was edging cautious, with 55 percent of Vetr user ratings bearish.

May has been good to shares in the pharmaceutical company, which is up more than 17 percent over the first 18 days of the month. This is in part due to a successful earnings report, in addition to the company's affirmation on positive guidance for 2017 that promised continued revenue growth.

Learn how crowdsourced ratings could help you time the market.

Currently, the Vetr crowd's average target price for Regeneron is down at $437.82, which is still above the average analyst target price of $431.90. Less than 2 percent of Vetr users are holding REGN in their watch lists.

Latest Ratings for REGN

Dec 2017Deutsche BankInitiates Coverage OnHold
Dec 2017CitigroupDowngradesBuyNeutral
Nov 2017BTIG ResearchMaintainsBuyBuy

View More Analyst Ratings for REGN
View the Latest Analyst Ratings

Posted-In: VetrBiotech Upgrades Health Care Price Target Crowdsourcing Analyst Ratings


Related Articles (REGN)

View Comments and Join the Discussion!